Urgent Field Safety Notice
SBN-RDS-MolecularLab-2022-008

RDS/**cobas**® 5800/6800/8800
Version 3
Nov-2023

Potential false negative Influenza A H1N1 Results with select Roche assays used on the cobas® 5800/6800/8800 systems

Product Name	**cobas**® SARS-CoV-2 & Influenza A/B qualitative assay for use on the **cobas**® 6800/8800 Systems (CE-IVD) GMMI: 09233474190 UDI: 00875197006674 **cobas**® SARS-CoV-2 & Influenza A/B qualitative nucleic acid test for use on the **cobas**® 5800/6800/8800 Systems (CE-IVD) GMMI: 09446125190 UDI: 00875197006827 **cobas**® Influenza A/B & RSV UC (Utility Channel) Qualitative nucleic acid test for use on the **cobas**® 6800/8800 Systems (CE-IVD) GMMI: 09233962190 UDI: 00875197006773
Production Identifier (Lot No./Serial No.)	N/A
SW Version	N/A
Type of Action	Field Safety Corrective Action (FSCA)

Dear Valued Customer,

Description of Situation

Roche previously announced the availability of **cobas**® SARS-CoV-2 & Influenza A/B v2 for use on **cobas**® 5800/6800/8800 Systems, CE-IVD (GMMI: 10033401190), with an updated influenza A design to improve inclusivity to the H1N1pdm09 variants detected in the influenza season 2022/2023.

The updated design consists of a dual-target approach for influenza A: one target is an updated version of the original influenza A design (matrix proteins 1 and 2) and the second target is a new design targeting another genomic region

Potential false negative Influenza A H1N1 Results with select Roche assays used on the cobas® 5800/6800/8800 systems

(polymerase basic protein 2). No changes have been implemented to the designs of the influenza B or SARS-CoV-2 targets when compared to the previous version of the assay.

Aside from the described design updates to the influenza A target, the new version of the test remains unchanged in its formulation and test procedure. In addition, the fully automated sample preparation (nucleic acid extraction, and purification), PCR amplification, and detection remain unchanged. The new version of the test is provided with the same negative and positive controls.

As previously communicated, Roche customer complaints alleging the generation of false negative Influenza A (Flu A) results and late Flu A Target Ct values with the **cobas**® SARS-CoV-2 & Influenza A/B qualitative assay for use on the **cobas**® 5800/6800/8800 Systems in relation to other platforms. These allegations are specific to recently circulating mutations (single or double mutation) in H1N1pdm09 pertinent to the region of interest to the aforementioned tests. The identified mismatches have been increasing among H1N1pdm09 sequences deposited to the GISAID database.

Important: the design of the **cobas**® Influenza A/B & RSV UC test on the **cobas**® 6800/8800 Systems, CE-IVD, which was impacted by the H1N1pdm09 variants detected in the previous influenza season, has not been updated as the test is being phased out and will be replaced by a new test under development, which is planned for CE mark accepting countries.

The CAPA investigation determined that the root cause of the issue is the influenza A target design of the assay, which was not inclusive for the current mutations that evolved subsequent to the development of the assays. These mutations result in delayed Ct values or even in failure to detect the presence of the Influenza A virus.

Actions taken by Roche Diagnostics (if applicable)

Roche continues to monitor the prevalence of circulating strains with one or both SNPs as part of the global surveillance.

Roche will inform about the availability of the new test, which is planned for 2Q2024.

Actions to be taken by the customer/user

Customers can order the new **cobas**® SARS-CoV-2 & Influenza A/B v2 for use on **cobas**® 5800/6800/8800 Systems, CE-IVD (GMMI: 10033401190) from their local affiliate organization.

Customers that utilize the **cobas**® Influenza A/B & RSV UC test on the **cobas**® 6800/8800 Systems, CE-IVD, must continue to follow instructions in the original Urgent Field Safety Notice (v1) as long as the the cobas® Influenza A/B & RSV UC test on the **cobas**® 6800/8800 Systems, CE-IVD, is utilized for testing.

- As a reminder, the “Procedural Limitations” section of the corresponding Instructions for Use states “As with any molecular test, mutations within the target regions of **cobas**® Influenza A/B & RSV UC could affect primer and/or probe binding resulting in failure to detect the presence of virus.” Additionally, the “Intended Use” sections note

Potential false negative Influenza A H1N1 Results with select Roche assays used on the cobas® 5800/6800/8800 systems

"Negative results do not preclude influenza virus infection and should not be used as the sole basis for treatment or other patient management decisions."

- Customers should monitor for negative influenza A results that are inconsistent with clinical presentation and/or other clinical and epidemiological information. Authorized or licensed Influenza NAATs are available for confirmation if clinically indicated for at-risk patients. The following tests are known not to be affected by these variants:
  cobas® Liat® System assays for influenza:
  - **cobas®** SARS-CoV-2 & Influenza A/B (CE-IVD); GMMI: 09211101190
  - **cobas®** Influenza A/B & RSV (CE-IVD); GMMI: 08160104190

- In the case of testing for Influenza, uncovering false results more than 1 day old would be unlikely to change patient management due to the acute nature of influenza and the short time period for therapeutic intervention. Therefore, reviewing previously generated influenza A negative results is not recommended.

Communication of this Field Safety Notice (if appropriate)

<If the recipient needs to forward the FSN to additional organizations/individuals then one or more of the following statements may be included:

This notice must be passed on to all those who need to be aware within your organization or to any organization/individual where the potentially affected devices have been distributed/supplied. (If appropriate).

Please transfer this notice to other organizations/individuals on which this action has an impact. (If appropriate).

Please maintain awareness of this notice and resulting action for an appropriate period to ensure the effectiveness of the corrective action. (If appropriate).>

The following statement is mandatory in FSNs for EEA countries but is not required for the rest of the World:

Include if applicable: The undersigned confirms that this notice has been notified to the appropriate Regulatory Agency.

We apologize for any inconvenience this may cause and hope for your understanding and your support.

Potential false negative Influenza A H1N1 Results with select Roche assays used on the cobas® 5800/6800/8800 systems

<closing salutations>,

Contact Details

To be completed locally:

Name
Title
Company Name
Address
Tel. +xx-xxx-xxxx xxxx
Email name@roche.com

Roche Molecular Systems, Inc.- SRN: US-MF-000018066 (legal manufacturer)
Roche Diagnostics GmbH- SRN: DE-AR-000006262 (EU authorized representative)